RU2016109633A - Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина - Google Patents
Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина Download PDFInfo
- Publication number
- RU2016109633A RU2016109633A RU2016109633A RU2016109633A RU2016109633A RU 2016109633 A RU2016109633 A RU 2016109633A RU 2016109633 A RU2016109633 A RU 2016109633A RU 2016109633 A RU2016109633 A RU 2016109633A RU 2016109633 A RU2016109633 A RU 2016109633A
- Authority
- RU
- Russia
- Prior art keywords
- subject
- dexmedetomidine
- delivering
- transdermal delivery
- sedative amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (20)
1. Способ, включающий нанесение на поверхность кожи неседированного субъекта устройства для трансдермальной доставки, содержащего:
композицию на основе дексмедетомидина, содержащую
дексмедетомидин; и
клей, склеивающий при надавливании; и
защитный слой,
причем композиция на основе дексмедетомидина составлена так, чтобы доставлять субъекту неседативное количество дексмедетомидина.
2. Способ по п. 1, включающий доставку субъекту неседативного количества дексмедетомидина в течение 1 дня или более.
3. Способ по п. 1, включающий доставку субъекту неседативного количества дексмедетомидина в течение 3 дней или более.
4. Способ по п. 1, включающий доставку субъекту неседативного количества дексмедетомидина в течение 7 дней или более.
5. Способ по п. 1, включающий доставку субъекту неседативного количества дексмедетомидина таким образом, чтобы показатель шкалы Рамсея для субъекта составлял не более 3 баллов.
6. Способ по п. 1, включающий доставку субъекту неседативного количества дексмедетомидина таким образом, чтобы показатель шкалы Рамсея для субъекта составлял не более 2 баллов.
7. Способ по п. 1, отличающийся тем, что субъект активен и способен реагировать на устные команды.
8. Способ по п. 1, включающий лечение субъекта от боли.
9. Способ по п. 1, включающий лечение субъекта от послеоперационной боли.
10. Способ по п. 1, включающий лечение субъекта от мигрени.
11. Способ по п. 1, включающий лечение субъекта от опиоидной зависимости.
12. Способ по п. 1, включающий доставку субъекту дексмедетомидина с помощью устройства для трансдермальной доставки со скоростью, которая изменяется от около 5 мкг/сутки до около 500 мкг/сутки.
13. Способ по п. 1, отличающийся тем, что клей, склеивающий при надавливании, содержит виниловый полимер.
14. Устройство для трансдермальной доставки, выполненное с возможностью применения в способе по любому из пп. 1-13.
15. Набор, содержащий устройство для трансдермальной доставки, выполненное с возможностью применения в способе по любому из пп. 1-13.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361887866P | 2013-10-07 | 2013-10-07 | |
US61/887,866 | 2013-10-07 | ||
PCT/US2014/059056 WO2015054061A1 (en) | 2013-10-07 | 2014-10-03 | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2016109633A true RU2016109633A (ru) | 2017-11-13 |
RU2648449C2 RU2648449C2 (ru) | 2018-03-26 |
Family
ID=52777128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016109633A RU2648449C2 (ru) | 2013-10-07 | 2014-10-03 | Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина |
Country Status (11)
Country | Link |
---|---|
US (1) | US10987342B2 (ru) |
EP (1) | EP3054930B1 (ru) |
JP (2) | JP6188933B2 (ru) |
KR (2) | KR101891185B1 (ru) |
CN (1) | CN105764496B (ru) |
BR (1) | BR112016006848A2 (ru) |
CA (1) | CA2924236C (ru) |
ES (1) | ES2847936T3 (ru) |
RU (1) | RU2648449C2 (ru) |
TW (1) | TWI629067B (ru) |
WO (1) | WO2015054061A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2648449C2 (ru) * | 2013-10-07 | 2018-03-26 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина |
US20150098997A1 (en) * | 2013-10-07 | 2015-04-09 | Teikoku Pharma Usa, Inc. | Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions |
JP2019534288A (ja) * | 2016-10-31 | 2019-11-28 | テイコク ファーマ ユーエスエー インコーポレーテッド | デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法 |
MX2019007923A (es) | 2016-12-31 | 2019-09-10 | Bioxcel Therapeutics Inc | Uso de dexmedetomidina sublingual para el tratamiento de la agitacion. |
US10792246B2 (en) | 2018-06-27 | 2020-10-06 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
CN112512634A (zh) * | 2019-04-24 | 2021-03-16 | 株式会社医药处方 | 含利多卡因的贴片 |
TWI772807B (zh) * | 2019-05-27 | 2022-08-01 | 日商救急藥品工業股份有限公司 | 外用製劑 |
US20240024288A1 (en) * | 2019-07-19 | 2024-01-25 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2101114B (en) | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
JPS60163811A (ja) | 1984-02-06 | 1985-08-26 | Watanabe Yakuhin Kogyo Kk | プロプラノロ−ル含有外用貼付剤 |
FI844786A0 (fi) | 1984-12-04 | 1984-12-04 | Farmos Oy | Terapeutiskt utnyttjbar foerening. |
FI864570A0 (fi) | 1986-11-11 | 1986-11-11 | Farmos Oy | Terapeutiskt anvaendbar foerening. |
GB2206880B (en) | 1987-07-16 | 1991-04-24 | Farmos Oy | Optical isomers of an imidazole derivative |
GB2215206B (en) | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US4994267A (en) * | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Transdermal acrylic multipolymer drug delivery system |
US5124157A (en) | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
US5217718A (en) | 1989-08-18 | 1993-06-08 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
FI894911A0 (fi) | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
US5304569A (en) | 1989-11-13 | 1994-04-19 | Orion-Yhtyma Oy | Compositions and their use in lowering intraocular pressure |
US5447947A (en) | 1990-02-26 | 1995-09-05 | Arc 1 | Compositions and methods of treatment of sympathetically maintained pain |
US5070084A (en) | 1990-02-26 | 1991-12-03 | Campbell James N | Treatment of sympathetically maintained pain |
JP2849937B2 (ja) | 1990-04-18 | 1999-01-27 | 日東電工株式会社 | 医療用貼付剤 |
GB9111732D0 (en) * | 1991-05-31 | 1991-07-24 | Orion Yhtymae Oy | The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs |
US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
AU2782592A (en) | 1991-10-15 | 1993-05-21 | Cygnus Therapeutic Systems | Thermal enhancement of transdermal drug administration |
US5459133A (en) | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
GB2281206A (en) | 1993-08-25 | 1995-03-01 | Orion Yhtymae Oy | Use of dexmedetomidine |
JPH0776526A (ja) | 1993-09-06 | 1995-03-20 | Sansei Seiyaku Kk | 乳酸エステルを含有する経皮吸収製剤 |
GB2290964A (en) | 1994-07-08 | 1996-01-17 | Arto Olavi Urtti | Transdermal drug delivery system |
ATE194281T1 (de) | 1994-09-14 | 2000-07-15 | Minnesota Mining & Mfg | Matrix für transdermale wirkstofffreisetzung |
US5635203A (en) | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
WO1996030416A1 (fr) | 1995-03-31 | 1996-10-03 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Procede de preparation d'adhesifs acryliques du genre solvant, sensibles a la pression, et adhesif medical sensible a la pression |
JP3534775B2 (ja) * | 1995-06-07 | 2004-06-07 | オーソ―マクニール ファーマシューティカル,インコーポレイテッド | 17−デアセチルノルゲスチマートを単独でまたはエストロゲンと組み合わせて投与するための経皮パッチおよび方法 |
US5891461A (en) | 1995-09-14 | 1999-04-06 | Cygnus, Inc. | Transdermal administration of olanzapine |
GB9521680D0 (en) | 1995-10-23 | 1996-01-03 | Orion Yhtymo Oy | New use of imidazole derivatives |
US7150881B2 (en) | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
AU750809B2 (en) * | 1997-09-26 | 2002-07-25 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
US6329369B1 (en) | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
US20020102291A1 (en) | 1997-12-15 | 2002-08-01 | Noven Pharmaceuticals, Inc. | Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
US20020068754A1 (en) | 1998-02-25 | 2002-06-06 | Olney John W. | Combination of adrenergic agonist and aryl-cyclo-alkanolamine for relieving chronic pain without adverse side effects |
US20020016319A1 (en) | 1998-02-25 | 2002-02-07 | Olney John W. | Combined adamantane derivative and adrenergic agonist for relief of chronic pain without adverse side effects |
US20020177592A1 (en) | 1998-02-25 | 2002-11-28 | Olney John W. | Combination of adrenergic agonist and tricyclo-alkylamine for relieving chronic pain without adverse side effects |
AR015744A1 (es) | 1998-04-01 | 2001-05-16 | Orion Corp | Uso de dexmedetomidina para sedacion en terapia intensiva |
WO2000019987A1 (en) | 1998-10-02 | 2000-04-13 | 3M Innovative Properties Company | Mucosal originated drug delivery systems and animal applications |
US7001609B1 (en) | 1998-10-02 | 2006-02-21 | Regents Of The University Of Minnesota | Mucosal originated drug delivery systems and animal applications |
ATE291907T1 (de) | 1998-10-20 | 2005-04-15 | Omeros Corp | Spülende lösung und methoden zur hemmung von schmerzen und entzündungen |
US20030170195A1 (en) * | 2000-01-10 | 2003-09-11 | Noven Pharmaceuticals, Inc. | Compositions and methods for drug delivery |
PE20001396A1 (es) | 1999-01-18 | 2000-12-23 | Gruenenthal Chemie | Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista |
DE19918106A1 (de) | 1999-04-22 | 2000-10-26 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern |
GB9913677D0 (en) | 1999-06-11 | 1999-08-11 | Imperial College | Formulation |
DE19938823A1 (de) | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
WO2001047512A2 (en) | 1999-12-08 | 2001-07-05 | Fluoro Probe, Inc. | Method for relieving pain associated with an internal disease site |
WO2001089448A2 (en) | 2000-03-28 | 2001-11-29 | Olney John W | Combination of adrenergic agonist and nmda antagonist for relieving chronic pain without adverse side effects |
US20050042194A1 (en) | 2000-05-11 | 2005-02-24 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
DE10138722C5 (de) | 2000-08-17 | 2017-05-24 | Schaeffler Technologies AG & Co. KG | Antriebsstrang |
US7635488B2 (en) | 2001-03-13 | 2009-12-22 | Dbv Technologies | Patches and uses thereof |
FR2832311B1 (fr) | 2001-11-21 | 2004-04-16 | Besins Int Belgique | Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations |
AR033748A1 (es) | 2002-05-15 | 2004-01-07 | Thalas Group Inc | Un dispositivo para la administracion transdermica de sustancias farmacologicamente activas que comprende dos capas adhesivas superpuestas y un procedimiento para prepararlo |
KR100511492B1 (ko) | 2002-10-11 | 2005-08-31 | 주식회사 태평양 | 에페리손, 톨페리손 또는 그것들의 염을 포함하는경피흡수제제 |
DK1589973T4 (da) | 2003-01-23 | 2013-04-08 | Shire Biopharmaceuticals Holdings Ireland Ltd | Formulering og fremgangsmåder til behandling af thrombocytæmi |
DE10305137A1 (de) | 2003-02-07 | 2004-08-26 | Novosis Ag | Transdermale therapeutische Abgabesysteme mit einem Butenolid |
US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US20050059664A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
US20050020600A1 (en) | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
JP4694967B2 (ja) | 2003-07-31 | 2011-06-08 | 久光製薬株式会社 | 貼付剤 |
CA2538445A1 (en) | 2003-09-12 | 2005-04-21 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US20050058696A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
UA84303C2 (ru) * | 2003-10-28 | 2008-10-10 | Новен Фармасьютикалз, Инк. | Система для трансдермальной доставки лечебного средства |
NZ552325A (en) | 2004-05-25 | 2010-11-26 | Sansrosa Pharmaceutical Dev Inc | The use of alpha 2 andrenoceptor agonists such as brimonidine for treating inflammatory skin disorders |
EP1809104A4 (en) | 2004-09-23 | 2009-04-29 | Alexander Michalow | METHODS FOR REGULATING NEUROTRANSMITTER SYSTEMS BY INDUCING COUNTER-ADAPTATIONS |
US20060166901A1 (en) | 2005-01-03 | 2006-07-27 | Yu Ruey J | Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids |
US20060210613A1 (en) | 2005-03-15 | 2006-09-21 | Carliss Richard D | Therapeutic wound care product |
WO2007035939A2 (en) | 2005-09-23 | 2007-03-29 | Alza Corporation | High enhancer-loading polyacrylate formulation for transdermal applications |
WO2007035942A2 (en) | 2005-09-23 | 2007-03-29 | Alza Corporation | Transdermal risperidone delivery system |
MX2008000486A (es) | 2005-10-24 | 2008-03-07 | Teikoku Pharma Usa Inc | Composiciones topicas para el alivio del dolor de n-2,3-trimetil-2-isopropilbutamida y metodos para usar las mismas. |
TWI389709B (zh) | 2005-12-01 | 2013-03-21 | Novartis Ag | 經皮治療系統 |
CN1994290B (zh) | 2006-01-04 | 2011-03-16 | 上海医药工业研究院 | 卡巴拉汀透皮贴剂及其制备方法 |
CA2637027A1 (en) | 2006-01-10 | 2007-07-19 | Ruey J. Yu | N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use |
ES2338716T3 (es) | 2006-01-27 | 2010-05-11 | F.Hoffmann-La Roche Ag | Uso de derivados de 4-imidazol para trastornos del snc. |
JP2009528289A (ja) | 2006-02-27 | 2009-08-06 | ミシャロウ、アレクサンダー | 対抗適応を誘発することにより神経伝達物質系を調節する方法 |
CN101460060A (zh) | 2006-03-01 | 2009-06-17 | 特莱斯特拉塔公司 | 局部治疗焦油响应性皮肤病用的组合物和方法 |
GB0611241D0 (en) | 2006-06-07 | 2006-07-19 | Daniolabs Ltd | The treatment of increased sebum production |
WO2008032718A1 (fr) * | 2006-09-11 | 2008-03-20 | Sekisui Chemical Co., Ltd. | Préparation adhésive |
US20090098191A1 (en) | 2007-10-16 | 2009-04-16 | Anderson Christopher G | Use of bases to stabilize transdermal formulations |
EP2818184B1 (en) | 2007-11-16 | 2018-10-31 | Allergan, Inc. | Compositions and methods for treating Purpura |
WO2009124755A1 (en) | 2008-04-08 | 2009-10-15 | European Molecular Biology Laboratory (Embl) | Compounds with novel medical uses and method of identifying such compounds |
US8889173B2 (en) * | 2008-04-18 | 2014-11-18 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
EP2286814B1 (en) | 2008-05-15 | 2013-10-16 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal preparation containing palonosetron |
WO2010063030A2 (en) | 2008-11-30 | 2010-06-03 | Feigelson, Daniel | Dermal application of vasoconstrictors |
EP2330903A4 (en) | 2008-07-28 | 2011-10-12 | Endogenx Inc | METHOD FOR TREATING PAIN USING AN ALPHA-2 ADRENEER AGONIST AND AN ENDOTHELINE ANTAGONIST |
US20100197694A1 (en) | 2008-08-01 | 2010-08-05 | Gerald Horn | Compositions and methods for treatment of diseases and conditions with increased vascular permeability |
US20110244058A1 (en) | 2008-08-01 | 2011-10-06 | Gerald Horn | Compositions and methods for treatment of pulmonary diseases and conditions |
US20120156244A1 (en) | 2008-08-01 | 2012-06-21 | Alpha Synergy Development Inc. | Nasal Compositions and Uses Thereof |
US20110257188A1 (en) | 2008-08-01 | 2011-10-20 | Gerald Horn | Compositions and methods for the treatment of nasal conditions |
US20100202979A1 (en) | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of pulmonary diseases and conditions |
EP2165706A1 (en) | 2008-09-18 | 2010-03-24 | BioAlliance Pharma | Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers. |
US9308203B2 (en) | 2008-10-01 | 2016-04-12 | Taiwan Biotech Co., Ltd. | Pressure sensitive adhesive matrix device or system for the treatment or prevention of onychomycosis or tinea pedis |
WO2010050211A1 (ja) | 2008-10-30 | 2010-05-06 | 国立大学法人 岡山大学 | 局所麻酔用組成物 |
US20120095104A1 (en) | 2008-11-30 | 2012-04-19 | Oron Zachar | Use of vasoconstrictors |
US20100196286A1 (en) | 2008-12-01 | 2010-08-05 | Armer Thomas A | Inhalation delivery methods and devices |
FR2942138A1 (fr) | 2009-02-16 | 2010-08-20 | Galderma Res & Dev | Association de composes pour le traitement ou la prevention des affections dermatologiques |
JP2012158521A (ja) | 2009-04-17 | 2012-08-23 | Kureha Corp | 外用剤 |
BRPI1010567A2 (pt) * | 2009-05-15 | 2016-03-15 | Recro Pharma Inc | composições sublinguais de dexmedetomidina e métodos de uso e aparelho que os emprega |
US8410140B2 (en) | 2009-06-01 | 2013-04-02 | The Regents Of The University Of Michigan | Anesthetic methods and compositions |
CN102753532B (zh) | 2009-12-09 | 2015-05-13 | I-技术有限公司 | 美托咪定的制备方法 |
NZ703808A (en) | 2010-01-08 | 2016-01-29 | Recro Pharma Inc | Topical transdermal dexmedetomidine compositions and methods of use thereof |
US9327105B2 (en) * | 2010-03-26 | 2016-05-03 | Itrace Biomedical Inc. | Active transdermal drug delivery system and the method thereof |
US20130029989A1 (en) | 2010-04-15 | 2013-01-31 | The Royal Institution For The Advancement Of Learning/Mcgill University | Topical treatments for pain |
US9023788B2 (en) | 2010-04-20 | 2015-05-05 | New York University | Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders |
EP2640389B1 (en) | 2010-11-17 | 2014-12-31 | Hexal AG | Transdermal therapeutic system comprising buprenorphine |
TWI433904B (zh) | 2011-01-12 | 2014-04-11 | Taiwan Biotech Co Ltd | 多奈哌齊經皮貼片 |
US20120309720A1 (en) | 2011-02-03 | 2012-12-06 | Alpha Synergy Development Inc. | Compositions and methods for treatment of glaucoma |
US20120202864A1 (en) | 2011-02-03 | 2012-08-09 | Alpha Synergy Development Inc. | Compositions and Methods for Treatment of Glaucoma |
ES2776146T3 (es) | 2011-04-18 | 2020-07-29 | Hisamitsu Pharmaceutical Co | Método para producir un parche adhesivo y parche adhesivo |
US20130096170A1 (en) * | 2011-10-14 | 2013-04-18 | Hospira, Inc. | Methods of treating pediatric patients using dexmedetomidine |
RU2014119919A (ru) | 2011-10-19 | 2015-11-27 | Галдерма С.А. | Способ лечения капиллярных гемангиом |
WO2013072763A2 (en) | 2011-11-16 | 2013-05-23 | Nometics Inc. | Non-sensitizing transdermal clonidine patch |
CN104470516A (zh) | 2011-12-11 | 2015-03-25 | 瑞克欧制药有限公司 | 鼻内右美托咪定组合物和其使用方法 |
US8242158B1 (en) * | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
HUE035312T2 (en) * | 2012-01-31 | 2018-05-02 | Gruenenthal Gmbh | Pharmaceutical patch (1R, 4R) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano [3,4- b] for transdermal administration of indole] -4-amine |
WO2013173317A1 (en) | 2012-05-14 | 2013-11-21 | Prospire, Llc | TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH α2-ADRENERGIC RECEPTOR AGONISTS |
BR112015004643A2 (pt) | 2012-08-31 | 2017-07-04 | Univ Midwestern | métodos e composições para ressucitação hipotensiva |
EP2919814A1 (en) | 2012-11-13 | 2015-09-23 | UCL Business Plc. | Adrenergic agonists for use in treating liver damage |
RU2648449C2 (ru) * | 2013-10-07 | 2018-03-26 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина |
TWI645866B (zh) | 2013-10-07 | 2019-01-01 | 美商帝國製藥美國股份有限公司 | 右美托咪啶經皮輸送裝置及使用其之方法 |
KR101891186B1 (ko) | 2013-10-07 | 2018-08-24 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 조성물을 포함하는 통증을 관리하기 위한 방법 및 조성물 |
WO2015093503A1 (ja) | 2013-12-18 | 2015-06-25 | 丸石製薬株式会社 | 含水型貼付剤 |
WO2016105449A1 (en) | 2014-12-22 | 2016-06-30 | Seth Lederman | Compounds for use as pain therapeutics |
-
2014
- 2014-10-03 RU RU2016109633A patent/RU2648449C2/ru active
- 2014-10-03 EP EP14851571.1A patent/EP3054930B1/en active Active
- 2014-10-03 KR KR1020167011597A patent/KR101891185B1/ko active IP Right Grant
- 2014-10-03 KR KR1020187023712A patent/KR20180095732A/ko not_active Application Discontinuation
- 2014-10-03 CN CN201480064110.2A patent/CN105764496B/zh active Active
- 2014-10-03 BR BR112016006848A patent/BR112016006848A2/pt not_active Application Discontinuation
- 2014-10-03 WO PCT/US2014/059056 patent/WO2015054061A1/en active Application Filing
- 2014-10-03 TW TW103134525A patent/TWI629067B/zh active
- 2014-10-03 CA CA2924236A patent/CA2924236C/en active Active
- 2014-10-03 JP JP2016520592A patent/JP6188933B2/ja active Active
- 2014-10-03 ES ES14851571T patent/ES2847936T3/es active Active
- 2014-10-03 US US14/505,936 patent/US10987342B2/en active Active
-
2017
- 2017-07-28 JP JP2017146425A patent/JP6522061B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
KR20160058957A (ko) | 2016-05-25 |
US20150098981A1 (en) | 2015-04-09 |
EP3054930A4 (en) | 2017-04-05 |
JP2017222701A (ja) | 2017-12-21 |
JP6522061B2 (ja) | 2019-05-29 |
EP3054930B1 (en) | 2020-12-02 |
TWI629067B (zh) | 2018-07-11 |
CA2924236C (en) | 2020-01-07 |
ES2847936T3 (es) | 2021-08-04 |
CN105764496B (zh) | 2020-09-25 |
CN105764496A (zh) | 2016-07-13 |
US10987342B2 (en) | 2021-04-27 |
KR20180095732A (ko) | 2018-08-27 |
RU2648449C2 (ru) | 2018-03-26 |
WO2015054061A1 (en) | 2015-04-16 |
BR112016006848A2 (pt) | 2017-08-01 |
KR101891185B1 (ko) | 2018-08-24 |
TW201526927A (zh) | 2015-07-16 |
JP6188933B2 (ja) | 2017-08-30 |
JP2016532644A (ja) | 2016-10-20 |
CA2924236A1 (en) | 2015-04-16 |
EP3054930A1 (en) | 2016-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016109633A (ru) | Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина | |
RU2016109631A (ru) | Способы и композиции для лечения боли, включающие трансдермальные композиции на основе дексмедетомидина | |
RU2016109632A (ru) | Способы и композиции для лечения абстинентных синдромов с использованием неседативных трансдермальных композиций на основе дексмедетомидина | |
RU2016109449A (ru) | Устройства для трансдермальной доставки дексмедетомидина и способы их применения | |
WO2018081812A3 (en) | METHODS OF PAIN MANAGEMENT USING TRANSDERMAL DEXMEDETOMIDINE DELIVERY DEVICES | |
CO6551749A2 (es) | Dispositivo y método para la aplicción tópica de composiciones terapéuticas o cosméticas | |
RU2016109634A (ru) | Способы и композиции для лечения синдрома дефицита внимания и гиперактивности, тревожности и бессонницы с применением трансдермальных композиций на основе дексмедетомидина | |
WO2011088333A3 (en) | Solid-forming local anesthetic formulations for pain control | |
WO2016090287A3 (en) | Transdermal cannabinoid formulations | |
EA201592246A1 (ru) | Трансдермальная система доставки | |
GB201700220D0 (en) | Gel compositions for transdermal delivery to maximise drug concentrations in the stratum corneum and serum and method of use thereof | |
TN2015000201A1 (en) | Transdermal delivery system | |
JP2016504368A5 (ru) | ||
IN2012DN01225A (ru) | ||
JP2019534288A5 (ru) | ||
WO2013049106A3 (en) | Reduction of implant infection via tunable stimulation of localized adaptive immune response | |
WO2010041884A3 (ko) | 치아 지각과민 방지용 조성물 | |
MX2016007470A (es) | Composicion antitranspirante anhidra en forma de aerosol que comprende un agente antitranspirante activo y un polimero etilenico de bloques, formador de pelicula, insoluble en agua. | |
IN2013MU03658A (ru) | ||
EA201300648A1 (ru) | Трансдермальная терапевтическая система (tts), содержащая ротиготин | |
WO2012142328A3 (en) | Polymer microsphere compositions for localized delivery of therapeutic agents | |
IN2013MU02532A (ru) | ||
WO2016149077A3 (en) | Fentanyl transdermal delivery system | |
WO2015063613A3 (en) | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents | |
WO2015008169A3 (en) | Device, system and method for delivery of a long-acting drug |